Viewing data from:

HALCINONIDE

ANDA

HALCINONIDE | A211027 | MYLAN PHARMACEUTICALS INC

1 strength0 unique patents0 unique exclusivities

Reference Listed Drug: HALOG(TE code: AB)

Medicare Part D Spending

CMS annual spending data for Halcinonide (2023)

Total Spending

$972K

Total Claims

1,059

Beneficiaries

412

Avg Cost/Unit

$8.21

Spending Trend

$287K(2019)→$1.5M(2020)→$1.6M(2021)→$2.0M(2022)→$972K(2023)

YoY Change:+4.6%

5yr CAGR:-2.9%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

API Supply Chain1 active DMF3 inactive

1 active API supplier hold Drug Master Files for this ingredient. Limited supplier base — potential supply chain risk.

FARMABIOS SPAHALCINONIDE

DMF 183522005

BRISTOL MYERS SQUIBB COInactiveHALCINONIDE BULK

DMF 22031973

SOCIETA ITALIANA CORTICOSTEROIDI SPAInactiveHALCINONIDE

DMF 74481988

FARMABOISInactiveHALCINONIDE

DMF 83351989

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Approval Letters

1 letter from Drugs@FDA

Date	Submission	Document
Sep 27, 2019	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (1)

#001 — 0.1%

0 patents0 exclusivities▴

CREAM;TOPICAL | Approved: Aug 12, 2019

No patent or exclusivity listings for this strength.